The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 randomized, active-controlled, multicenter trial to assess the safety and efficacy of RRx-001 + irinotecan vs. regorafenib + irinotecan in third/fourth-line colorectal cancer.
 
Tony R. Reid
Employment - EpicentRx
Leadership - EpicentRx
Stock and Other Ownership Interests - EpicentRx
Research Funding - EpicentRx
Patents, Royalties, Other Intellectual Property - Patents
 
Nacer Abrouk
Consulting or Advisory Role - EpicentRx
 
Bryan Oronsky
Employment - EpicentRx
Leadership - EpicentRx
Stock and Other Ownership Interests - EpicentRx
Research Funding - EpicentRx
Patents, Royalties, Other Intellectual Property - Patents
 
Scott Caroen
Employment - EpicentRx
Stock and Other Ownership Interests - EpicentRx
Patents, Royalties, Other Intellectual Property - Scott Caroen is on patents relating to EpicentRx, Inc., technologies.
 
George A. Fisher
Stock and Other Ownership Interests - Seagen (I)
Honoraria - echina health
Consulting or Advisory Role - Genentech/Roche; Ipsen; Merck; Taiho Pharmaceutical
Research Funding - Genentech/Roche (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Merck; Roche/Genentech
Other Relationship - AstraZeneca; CytomX Therapeutics; Hutchison MediPharma; Silenseed; Taiho Pharmaceutical; Terumo Clinical Supply